MAY 02, 2020 11:26 PM PDT

Glioblastoma Treatment Using Schizophrenic Drug Plus Radiation

WRITTEN BY: Nouran Amin

A therapeutic used for the treatment of schizophrenia could be a gateway for targeting glioblastoma, one of the deadliest brain tumors. Findings were published in the Proceedings of the National Academy of Sciences (PNAS) and discusses how the schizophrenic drug, trifluoperazine, could be used in combination with radiation to eradicate glioblastoma tumors.

Learn more about glioblastoma:

"While radiotherapy is one of the few treatments that prolong survival in glioblastoma patients, radiation alone does very little in treating the disease in our models because we are dealing with highly aggressive tumors," said the study's senior author, Dr. Frank Pajonk, a professor of radiation oncology at the David Geffen School of Medicine at UCLA and a member of the Jonsson Cancer Center. "The drug trifluoperazine by itself does not do much either, but we found when you combine them, they become highly efficient. Importantly, the drug does not sensitize cells to radiation but rather prevents the occurrence of resistant glioma stem cells."

The use of radiative therapy has been a critical component of cancer treatment. However, tumor cells that are known to develop resistance to drugs can also develop resistance to radiation. This resistance is believed to be the result of “phenotype conversion”—where healthy cells become tumor cells and defeating the purpose.

"Many preclinical glioblastoma studies report fairly small increases in overall survival in mice, and that rarely translates into benefits for patients," said Pajonk, who is also a member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA. "But here we see pretty drastic effects in improved overall survival, and I find that very encouraging. It gives us hope that this is all going to translate into a benefit for people."

Source: Science Daily

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
MAR 03, 2021
Drug Discovery & Development
Keeping HIV Latent
MAR 03, 2021
Keeping HIV Latent
When (HIV) human immunodeficiency virus infects cells, it can go to sleep as opposed to make viral copies of itself&mdas ...
MAR 09, 2021
Drug Discovery & Development
Personalized Psychedelic Assisted-Therapy
MAR 09, 2021
Personalized Psychedelic Assisted-Therapy
Psychedelics have long been known for their therapeutic in treating mental health disorders. However, there remains a co ...
APR 15, 2021
Drug Discovery & Development
Magic Mushroom Therapy and Antidepressants Produce Similar Results
APR 15, 2021
Magic Mushroom Therapy and Antidepressants Produce Similar Results
In recent years, psilocybin (the psychoactive ingredient in 'magic mushrooms') has gained increasing amounts of ...
APR 22, 2021
Drug Discovery & Development
New Method To Fast Track Drug Development
APR 22, 2021
New Method To Fast Track Drug Development
The time it takes to respond to disease outbreaks is critical. But designing drugs to combat these disease outbreaks is ...
MAY 06, 2021
Drug Discovery & Development
Are Hallucinations Necessary for Psychedelics to Treat Depression?
MAY 06, 2021
Are Hallucinations Necessary for Psychedelics to Treat Depression?
Many who work with psychedelics say that hallucinations, or psychedelic experiences, are an integral part of psychedelic ...
MAY 27, 2021
Neuroscience
Research Less Likely to Be True is Cited More
MAY 27, 2021
Research Less Likely to Be True is Cited More
Researchers from the University of California San Diego have found that non-replicable data is cited 153 times more ofte ...
Loading Comments...